Eisai Korea Inc.
Clinical trials sponsored by Eisai Korea Inc., explained in plain language.
-
Large-Scale korean study monitors Real-World safety of arthritis and colitis drug
Disease control Recruiting nowThis study is checking the safety and effectiveness of the drug Jyseleca (filgotinib) in Korean patients with rheumatoid arthritis or ulcerative colitis. About 2040 people will take the drug as prescribed by their doctor, and researchers will track side effects and how well the d…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for ulcerative colitis: korean study tests daily pill to calm flare-ups
Disease control Recruiting nowThis study tests a daily pill called filgotinib (200 mg) in about 94 Korean adults with moderate-to-severe ulcerative colitis. The main goal is to see if it can bring the disease into remission (quiet down symptoms) by week 10 or 22. Participants take the pill once a day and are …
Phase: PHASE4 • Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
Disease control Recruiting nowThis study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling, small bleeds, and larger hemorrhages. Researchers will use real-world data from a national registry. The goal is to understand how often t…
Sponsor: Eisai Korea Inc. • Aim: Disease control
Last updated May 05, 2026 11:52 UTC